U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H19NO4
Molecular Weight 205.2515
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXPANTHENOL

SMILES

CC(C)(CO)[C@@H](O)C(=O)NCCCO

InChI

InChIKey=SNPLKNRPJHDVJA-ZETCQYMHSA-N
InChI=1S/C9H19NO4/c1-9(2,6-12)7(13)8(14)10-4-3-5-11/h7,11-13H,3-6H2,1-2H3,(H,10,14)/t7-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H19NO4
Molecular Weight 205.2515
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created using several sources including: http://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+21982351; https://www.aako.nl/product-groups/personal-hair-care/products/active-ingredient/dl-panthenol-100; www.fda.gov/downloads/cosmetics/guidanceregulation/guidancedocuments/ucm208412.pdf; http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/over-the-counterotcdrugs/statusofotcrulemakings/ucm078437.pdf; http://www.ncbi.nlm.nih.gov/pubmed/20061726; http://crystalderma.rs/panthenol-care-and-regeneration/; http://tri-k.com/dl-panthenol

Panthenol (pantothenol) is an alcohol form of the B5 vitamin pantothenic acid. It easily penetrates the skin retaining water and is a humectant, emollient and moisturizer. Panthenol mitigates signs of inflammation and stimulates epithelization. Panthenol comes in two enantiomers, D and L. Only D-panthenol (dexpanthenol) is biologically active, however both forms have moisturizing properties. Because of the ability to attract and hold moisture panthenol is used in skincare products as a humectant. It also has a role as provitamin (called pro-vitamin B5) and is used as a vitamin supplement in complex ( M.V.I. ADULT injection, Hospira Worldwide, Inc.) and alone, and as a cholinergic drug. Panthenol is a highly viscous transparent liquid at room temperature, but salts of pantothenic acid (sodium pantothenate) are powders (typically white). It is soluble in water, alcohol, propylene glycol, ether and chloroform, and slightly soluble in glycerin. Panthenol mixes readily with many different types of ingredients, making it a versatile ingredient to be used in formulas because it improves skin’s barrier function and maintains the proliferation of fibroblasts. In organisms it is quickly oxidized to pantothenate (pantothenic acid). Defficiency of Vitamin B5 results in many dermatological disorder. Due to the fact that only D-Panthenol is converted to Vitamin B5 and not L-Panthenol, the racemic mixture of D- and L- panthenol (DL-panthenol) has only half of the physiological activity of the D-Panthenol. These include stimulation of epithelisation, wound healing effect and anti-infl ammatory effect. Panthenol is FDA approved for cosmetic use and comes either in D form, or as a racemic mixture. It is also in the FDA list of over-the-counter drug products that are not generally recognized as safe and effective or are misbranded: as "Insect Bite and Sting Drug Products" and "Poison Ivy, Poison Oak, and Poison Sumac Drug Products".

Originator

Curator's Comment: The product line was first introduced in Europe in 1946 by Hoffmann-La Roche of Switzerland. The brand name was bought by Procter&Gamble in 1985 to compete in the 'beauty product' market (Dyer, Davis (2004). Rising Tide: lessons from 165 years of brand building at Procter & Gamble. Harvard Business Press. p. 277) # Hoffmann-La Roche, Switzerland

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Inactive ingredient
REVERSE IT KIT

Approved Use

USE HELPS PROTECT AGAINST SUNBURN

Launch Date

2014
Preventing
BABOR BABORGANIC AGE PREVENTING BODY CREAM

Approved Use

Unknown

Launch Date

1954
Doses

Doses

DosePopulationAdverse events​
5 % 2 times / day multiple, topical
Recommended
Dose: 5 %, 2 times / day
Route: topical
Route: multiple
Dose: 5 %, 2 times / day
Sources:
healthy, 18–45
Health Status: healthy
Age Group: 18–45
Sex: M+F
Sources:
5 % multiple, topical
Recommended
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy
Health Status: unhealthy
Sources:
Disc. AE: Allergic contact dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic contact dermatitis
Sources:
5 % multiple, topical
Recommended
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy
Health Status: unhealthy
Sources:
Disc. AE: Allergic contact dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic contact dermatitis
Sources:
AEs

AEs

AESignificanceDosePopulation
Allergic contact dermatitis Disc. AE
5 % multiple, topical
Recommended
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy
Health Status: unhealthy
Sources:
Allergic contact dermatitis Disc. AE
5 % multiple, topical
Recommended
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Simultaneous determination of pantothenic acid and D-panthenol in cosmetics by high performance liquid chromatography].
2010-11
Impact of repeated four-monthly anthelmintic treatment on Plasmodium infection in preschool children: a double-blind placebo-controlled randomized trial.
2010-09-21
[Severe inflammation of the muzzle caused by a nose ring in a breeding bull].
2010-09
A search for mosquito larvicidal compounds by blocking the sterol carrying protein, AeSCP-2, through computational screening and docking strategies.
2010-07
[Simulation of corneal epithelial injuries by mechanical and corrosive damage : Influence of fetal bovine serum and dexpanthenol on epithelial regeneration in a cell culture model].
2010-06
Identifying essential genes in bacterial metabolic networks with machine learning methods.
2010-05-03
Final report of the safety assessment of allantoin and its related complexes.
2010-05
Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.
2010-04-23
The nitric acid burn trauma of the skin.
2010-04
Tissue extract from Eisenia foetida as a wound-healing agent.
2010-03
[Glued eyelids by cyanoacrylate glue (superglue)].
2010-02
The effects of a daily facial lotion containing vitamins B3 and E and provitamin B5 on the facial skin of Indian women: a randomized, double-blind trial.
2010-01-12
Photoprotective potential of emulsions formulated with Buriti oil (Mauritia flexuosa) against UV irradiation on keratinocytes and fibroblasts cell lines.
2010-01
Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses.
2010
A management dilemma: infectious keratitis associated with soft contact lens use and dubious treatment compliance.
2010
Conservative treatment of a patient with epidermolysis bullosa presenting as bart syndrome: a case report.
2010
Water-filtered infrared-A (wIRA) in acute and chronic wounds.
2009-12-16
Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts.
2009-11
Antioxidant systems and oxidative stress in the testes.
2009-10-02
Common cosmeceuticals.
2009-08-22
[Effects of panthenol and carnitine on aldehyde metabolic enzymes in rats with tetrachloromethane-induced liver injury].
2009-05-16
Patterns of soil-transmitted helminth infection and impact of four-monthly albendazole treatments in preschool children from semi-urban communities in Nigeria: a double-blind placebo-controlled randomised trial.
2009-02-19
Tracheostomy cannulas and voice prosthesis.
2009
Vitiligo treatment with vitamins, minerals and polyphenol supplementation.
2009
Oxymetazoline plus dexpanthenol in nasal congestion.
2008-12
Miscellaneous.
2008-10
Skin protection creams in medical settings: successful or evil?
2008-07-25
Safety and efficacy of a new honey ointment on diabetic foot ulcers: a prospective pilot study.
2008-03
Therapy of acute wounds with water-filtered infrared-A (wIRA).
2007-12-28
A phase III trial comparing an anionic phospholipid-based cream and aloe vera-based gel in the prevention of radiation dermatitis in pediatric patients.
2007-12-19
In vitro human nail penetration and kinetics of panthenol.
2007-08
Development and validation of reversed phase high performance liquid chromatography method for determination of dexpanthenol in pharmaceutical formulations.
2007-02-19
[Clinical evaluation of the efficacy and tolerability of the ''NoAll Bimbi Pasta Trattante'' barrier cream in napkin dermatitis].
2007-02
Allergic contact dermatitis to panthenol and cocamidopropyl PG dimonium chloride phosphate in a facial hydrating lotion.
2006-12
Facilitating facial retinization through barrier improvement.
2006-10
Pharmacologic interventions in aging hair.
2006
Xenobiotics in vitro: the influence of L-cystine, pantothenat, and miliacin on metabolic and proliferative capacity of keratinocytes.
2006
Evaluation of the ultrasound influence in the cutaneous penetration of d-panthenol: test in vitro.
2005-01
Conservative procedures in skin reconstitution.
2005
[The influence of panthotenic acid mitochondrial oxidation and oxidative phosphorylation in liver of rats with alimentary obesity].
2004
[Gel with provitamin B5 applied during tests with the Goldmann triple-mirror].
2003
[Clinical evaluation of provitamin B5 drops and gel for postoperative treatment of corneal and conjuctival injuries].
2003
Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation.
2002-12
Colorimetric and fluorimetric methods for determination of panthenol in cosmetic and pharmaceutical formulation.
2002-02-01
Abuse of silver-nitrate solution for planing periorbital folds.
2002-02
Topical use of dexpanthenol in skin disorders.
2002
Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose.
2001-10
Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study.
2000-07
[Clinical study of the effectiveness of a dexpanthenol containing artificial tears solution (Siccaprotect) in treatment of dry eyes].
1996-08-01
[The metabolism of panthenol in patients with postoperative intestinal atony].
1990-12
Patents

Sample Use Guides

Anti-aging body cream (1.8 ml panthenol/200 ml) for dry skin used to treat the skin and leave it soft and supple. Repairs the skin's protective barrier, strengthening it against external influences.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:47:15 GMT 2025
Edited
by admin
on Mon Mar 31 17:47:15 GMT 2025
Record UNII
1O6C93RI7Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
D-PANTHENOL
VANDF  
Preferred Name English
DEXPANTHENOL
EP   FCC   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
CORNERGEL
Common Name English
D-PANTOTHENYL ALCOHOL
Systematic Name English
DEXPANTHENOL [ORANGE BOOK]
Common Name English
PROVITAMIN B5
Common Name English
D-PANTHENOL 50
Common Name English
DEXPANTHENOL [USAN]
Common Name English
PROPANOLAMINE, N-PANTOYL-
Common Name English
DOLOBENE
Common Name English
DEXPANTHENOL [USP MONOGRAPH]
Common Name English
D-PANTOTHENOL
Systematic Name English
dexpanthenol [INN]
Common Name English
BUTYRAMIDE, 2,4-DIHYDROXY-N-(3-HYDROXYPROPYL)-3,3-DIMETHYL-, D-(+)-
Common Name English
DEXPANTHENOL [HSDB]
Common Name English
DEXPANTHENOL [USP-RS]
Common Name English
(+)-PANTHENOL
Systematic Name English
BUTANAMIDE, 2,4-DIHYDROXY-N-(3-HYDROXYPROPYL)-3,3-DIMETHYL-, (2R)-
Systematic Name English
MOTILYN
Common Name English
DEXPANTHENOL [EP MONOGRAPH]
Common Name English
PANTHENOL 50W
Common Name English
BEPANTHENE
Common Name English
BEPANTOL
Common Name English
DEXPANTHENOL [MI]
Common Name English
BUTANAMIDE, 2,4-DIHYDROXY-N-(3-HYDROXYPROPYL)-3,3-DIMETHYL-, (R)-
Systematic Name English
D(+)-PANTHENOL
Common Name English
COZYME
Common Name English
PANTHENOL, (+)-
Systematic Name English
PANTOL
Common Name English
PANTHENOL [JAN]
Common Name English
URUPAN
Common Name English
DEXPANTHENOL [MART.]
Common Name English
D-P-A INJECTION
Common Name English
PANADON
Common Name English
D-PANTHENOL [VANDF]
Common Name English
DEXPANTHENOL [VANDF]
Common Name English
DEXPANTENOL
Common Name English
Dexpanthenol [WHO-DD]
Common Name English
INTRAPAN
Common Name English
ILOPAN
Brand Name English
PANTHENOL, (R)-
Systematic Name English
PROVITAMIN B
Common Name English
ZENTINIC
Common Name English
ALCOPAN 250
Common Name English
D(+)-.ALPHA.,.GAMMA.-DIHYDROXY-N-(3-HYDROXYPROPYL)-.BETA.,.BETA.-DIMETHYLBUTYRAMIDE
Common Name English
NSC-302962
Code English
PANTOTHENYL ALCOHOL
Systematic Name English
THENALTON
Common Name English
PANTHODERM
Common Name English
BEPANTHEN
Common Name English
SYNAPAN
Common Name English
DEXPANTHENOL [FCC]
Common Name English
D(+)-2,4-DIHYDROXY-N-(3-HYDROXYPROPYL)-3,3-DIMETHYLBUTYRAMIDE
Common Name English
(2R)-2,4-DIHYDROXY-N-(3-HYDROXYPROPYL)-3,3-DIMETHYLBUTANAMIDE
Systematic Name English
PANTENYL
Common Name English
D(+)-PANTOTHENYL ALCOHOL
Common Name English
Classification Tree Code System Code
WHO-VATC QS01XA12
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
WHO-VATC QD03AX03
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
WHO-ATC A11HA30
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
CFR 21 CFR 310.527
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
LIVERTOX 292
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
WHO-ATC S01XA12
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
WHO-VATC QA11HA30
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
WHO-ATC D03AX03
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
NCI_THESAURUS C26017
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
Code System Code Type Description
CAS
50584-68-4
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
SUPERSEDED
CAS
81-13-0
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
CAS
1113-70-8
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
SUPERSEDED
RS_ITEM_NUM
1179504
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-327-3
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
DRUG CENTRAL
838
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
PUBCHEM
131204
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
HSDB
296
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
SMS_ID
100000092075
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200979
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
NSC
302962
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
CHEBI
27373
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
RXCUI
22701
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY RxNorm
EVMPD
SUB07042MIG
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
INN
1023
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
CAS
17307-32-3
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
SUPERSEDED
EPA CompTox
DTXSID3022906
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
DRUG BANK
DB09357
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
FDA UNII
1O6C93RI7Z
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
MESH
C007288
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
NCI_THESAURUS
C47481
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
DAILYMED
1O6C93RI7Z
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY
MERCK INDEX
m4219
Created by admin on Mon Mar 31 17:47:15 GMT 2025 , Edited by admin on Mon Mar 31 17:47:15 GMT 2025
PRIMARY Merck Index
Related Record Type Details
RACEMATE -> ENANTIOMER
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY